Supplement company merging certain business operations with Zuellig Botanical Extracts in a deal worth $66 mil., the companies announce Dec. 9. In addition to Zuellig, the deal includes Wilcox Drug (Wilcox Natural Products) and ZetaPharm, and creates what the companies call the "leading U.S. supplier of herbal extracts, botanical raw materials and related products." Long Beach, Calif.-based Zuellig markets and distributes herbal extracts and other products, Wilcox cultivates and sources wild-crafted botanical raw materials and ZetaPharm "imports and distributes bulk vitamins, nutritional supplements, pharmaceutical ingredients and food additives." To "focus corporate resources...Hauser will discontinue its paclitaxel business and at the end of the current fiscal quarter will incur a one-time charge of approximately $25 mil.-$30 mil.," the companies note
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
Highlights from Day Three of the BIO International Convention include the realities of MFN pricing, AstraZeneca's R&D plans for obesity, the need for resources for the FDA's rare disease hub and reactions to the Commissioner's National Priority Review Voucher program.
There is a place for using external reference pricing to set prices of advanced therapies, but any such mechanism must take into account the specificities of the Brazilian market and health system.
Lerodalcibep and palbociclib are among the latest new drugs that the European Medicines Agency has started to review for potential EU marketing authorization.
